Founded in 2020, Neomorph has been garnering interest from big pharma for its discovery platform. Last year, it signed separate multi-billion dollar partnerships with big-wigs Biogen BIIB and Novo ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion in milestone payments. AbbVie and Neomorph have announced a collaboration ...

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Neomorph, Inc., today announced the appointment of Dr. Klaus Wagner as Chief Medical Officer. Dr. Wagner is a seasoned biotech executive with extensive ...

Neomorph Inc. has signed another billion-dollar deal to develop molecular glue degraders, this time with Abbvie Inc. It’s the third agreement in the past year the five-year-old company has signed with ...

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see new data on a next-generation obesity candidate from ...

The North Chicago-based company announced today it entered into an option-to-license agreement with San Diego-based Neomorph to develop novel therapies for cancers and immune diseases. Neomorph ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...

"At Neomorph, we have spent years building a unique molecular glue platform with broad coverage of the proteome," said Phil Chamberlain, DPhil, Co-Founder, President, and Chief Executive Officer ...